Preclinical and Clinical Phase I Studies of a New Recombinant Filgrastim (BK0023) in Comparison with Neupogen®

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2014 Feb 22

PMID 24555723

Citations 10

Authors

Davide Crobu

Gaia Spinetti

Rodolfo Schrepfer

Giancarlo Tonon

Gloria Saccani Jotti

Pierluigi Onali

Simona Dedoni

Gaetano Orsini

Andrea Di Stefano

Affiliations

Soon will be listed here.

Abstract

Background: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with nonmyeloid malignancies. In addition to its role in the regulation of granulopoiesis, treatment with G-CSF is considered the standard approach to mobilize CD34 positive (CD34+) mononuclear cells for reconstituting hemopoietic ability for bone marrow transplantation. An intended biosimilar filgrastim (coded BK0023) was produced in GMP conditions by E.coli fermentation according to an original recombinant process and showed physico-chemical properties and purity profile similar to Neupogen®, a commercial preparation of filgrastim. The aim of the present study was to demonstrate the comparability of BK0023 to Neupogen® in terms of both in vitro biological activities and in vivo toxicology, pharmacokinetics and pharmacodynamics.

Methods: Cell proliferation and radioligand binding assays were conducted in NFS-60 cells to compare the biological activity and functional interaction with the G-CSF receptor in vitro, while preclinical in vivo studies, including pharmacokinetics and pharmacodynamics after repeated dose were performed in normal and neutropenic rats. A phase I study was carried out in healthy male volunteers treated by multiple-dose subcutaneous administration of BK0023 and Neupogen® to evaluate their pharmacodynamic effects as well as their pharmacokinetic and safety profile and to demonstrate their pharmacodynamic equivalence and pharmacokinetic bioequivalence.

Results: The results reported in this work demonstrate that BK0023 is comparable in terms of biological activity, efficacy and safety to Neupogen®.

Conclusions: BK0023 has the same pharmacokinetic profile, efficacy and safety as the reference commercial filgrastim Neupogen® and therefore could be further developed to become a convenient option to treat neutropenia in oncological patients.

Citing Articles

Nupur N, Joshi S, Gulliarme D, Rathore A Front Bioeng Biotechnol. 2022; 10:832059.

PMID: 35223794 PMC: 8865741. DOI: 10.3389/fbioe.2022.832059.

Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice.

Ustyuzhanina N, Anisimova N, Bilan M, Donenko F, Morozevich G, Yashunskiy D Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832856 PMC: 8623974. DOI: 10.3390/ph14111074.

Effect of Filgrastim on adult male rats' fertility and reproductive performance.

Saber S, Alduweesh N, Abd El-Rahman H, Omar A Saudi J Biol Sci. 2021; 28(4):2558-2565.

PMID: 33911967 PMC: 8071903. DOI: 10.1016/j.sjbs.2021.01.060.

Influence of Modified Fucoidan and Related Sulfated Oligosaccharides on Hematopoiesis in Cyclophosphamide-Induced Mice.

Anisimova N, Ustyuzhanina N, Bilan M, Donenko F, Ushakova N, Usov A Mar Drugs. 2018; 16(9).

PMID: 30216993 PMC: 6164909. DOI: 10.3390/md16090333.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.

Waller C, Tiessen R, Lawrence T, Shaw A, Liu M, Sharma R J Cancer Res Clin Oncol. 2018; 144(6):1087-1095.

PMID: 29671069 DOI: 10.1007/s00432-018-2643-3.

References

Tanaka R, Matsudaira T, Aizawa J, Ebihara Y, Muraoka K, Tsuji K . Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG-CSF) in normal volunteers: dose-effect relationship for filgrastim with the character of mobilized PBPC. Br J Haematol. 1996; 92(4):795-803. DOI: 10.1046/j.1365-2141.1996.412949.x. View

Tanaka H, Tanaka Y, Shinagawa K, Yamagishi Y, Ohtaki K, Asano K . Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine. 1997; 9(5):360-9. DOI: 10.1006/cyto.1996.0177. View

Fukunaga R, Nagata S . Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. J Biol Chem. 1990; 265(23):14008-15. View

Nohynek G, Plard J, Wells M, Zerial A, Roquet F . Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Cancer Chemother Pharmacol. 1997; 39(3):259-66. DOI: 10.1007/s002800050570. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

Pozzuolo S, Breme U, Salis B, Taylor G, Tonon G, Orsini G . Efficient bacterial expression of fusion proteins and their selective processing by a recombinant Kex-1 protease. Protein Expr Purif. 2008; 59(2):334-41. DOI: 10.1016/j.pep.2008.02.018. View

Scaramuzza S, Tonon G, Olianas A, Messana I, Schrepfer R, Orsini G . A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization. J Control Release. 2012; 164(3):355-63. DOI: 10.1016/j.jconrel.2012.06.026. View

Schuirmann D . A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15(6):657-80. DOI: 10.1007/BF01068419. View

Mackie A, Losordo D . CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J. 2011; 38(5):474-85. PMC: 3231531. View

10.

Borleffs J, Bosschaert M, Vrehen H, Schneider M, van Strijp J, Small M . Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clin Ther. 1998; 20(4):722-36. DOI: 10.1016/s0149-2918(98)80135-5. View

11.

Frampton J, Lee C, Faulds D . Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs. 1994; 48(5):731-60. DOI: 10.2165/00003495-199448050-00007. View

12.

Welte K, Gabrilove J, Bronchud M, PLATZER E, Morstyn G . Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996; 88(6):1907-29. View

13.

Yoshioka T, Takahashi M, Shiba Y, Suzuki C, Morimoto H, Izawa A . Granulocyte colony-stimulating factor (G-CSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice. Cardiovasc Res. 2006; 70(1):61-9. DOI: 10.1016/j.cardiores.2005.12.013. View

14.

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

15.

Sarkar C, Lowenhaupt K, Horan T, Boone T, Tidor B, Lauffenburger D . Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat Biotechnol. 2002; 20(9):908-13. DOI: 10.1038/nbt725. View

16.

Garcia-Carbonero R, Mayordomo J, Tornamira M, Lopez-Brea M, Rueda A, Guillem V . Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001; 93(1):31-8. DOI: 10.1093/jnci/93.1.31. View

17.

Schabitz W, Schneider A . New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci. 2007; 28(4):157-61. DOI: 10.1016/j.tips.2007.02.007. View

18.

To L, Haylock D, Simmons P, Juttner C . The biology and clinical uses of blood stem cells. Blood. 1997; 89(7):2233-58. View

19.

. Kruskal-Wallis test: BASIC computer program to perform nonparametric one-way analysis of variance and multiple comparisons on ranks of several independent samples. Comput Methods Programs Biomed. 1986; 23(1):57-62. DOI: 10.1016/0169-2607(86)90081-7. View

20.

Christopher M, Link D . Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. J Bone Miner Res. 2008; 23(11):1765-74. PMC: 2685485. DOI: 10.1359/jbmr.080612. View